Arcutis (ARQT) CFO Vairavan Latha Sells 435 Shares

What Happened
Vairavan Latha, Chief Financial Officer of Arcutis Biotherapeutics (ARQT), reported an open-market sale of 435 shares on 2026-05-11 at $21.05 per share, for proceeds of $9,157. The filing indicates the sale was to cover tax withholding obligations tied to the vesting of restricted stock units (RSUs), not a discretionary cash-sale for investment purposes.

Key Details

• Transaction type: Sale (S) — open market/private sale reported on Form 4.
• Date of transaction: 2026-05-11; Form 4 filed: 2026-05-13 (within typical Form 4 deadline).
• Price and amount: 435 shares @ $21.05 ⇒ total proceeds ≈ $9,157.
• Footnote: F1 — sale was to cover tax withholding from RSU vesting.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Accession: 0002065881-26-000004 (Form 4 filed with the SEC).

Context
Sales to cover tax withholding after RSU vesting are common and generally considered routine administrative transactions rather than clear signals of insider bearishness. For retail investors, a small, tax-related sale like this is typically less informative than voluntary purchases by insiders.